Phathom's Operating Loss Shrinks To $85,000 As Voquezna Revenue Climbs 71%
The heartburn-drug maker posted a second straight quarter of positive operating cash flow and held its full-year revenue forecast of $310 million to $325 million.
Phathom Pharmaceuticals, which sells the heartburn drug Voquezna, cut its third-quarter operating loss to $85,000 from $15.3 million a year earlier, the company said Thursday in an 8-K. Net revenue rose 71% to $84.7 million, and operating cash flow stayed positive for a second consecutive quarter.
Revenue up, losses narrower
Net revenue of $84.7 million compares with $49.5 million in the third quarter of 2025 and is 14% above the second quarter of 2026. Net loss fell to $13.9 million from $30.0 million.
On an adjusted basis, which strips out stock pay and non-cash interest on its revenue-interest financing, Phathom earned $3.0 million, against an adjusted net loss of $11.2 million a year earlier. Operating expenses rose to $66.4 million from $58.6 million, which the company tied to clinical development and a bigger sales push.
Cash was $184.6 million on September 30, up $2.1 million from June 30. Phathom said cash on hand plus future operating cash should cover all its debt obligations without new debt or equity financing.
It maintained full-year 2026 guidance: net revenue of $310 million to $325 million, gross margin of about 80%, and adjusted operating expenses of $235 million to $245 million.
Two million prescriptions and a $0 copay
Phathom is a commercial-stage drugmaker whose Voquezna tablets and paks contain vonoprazan, an acid blocker approved for reflux disease and H. pylori infection. About 380,000 prescriptions were filled in the quarter, roughly 248,000 covered by insurance and 132,000 cash-pay. Covered volume rose about 19% from the second quarter.
Total prescriptions since launch passed 2 million through October 16. The company rolled out "Access First" field messaging and, at quarter's end, a BlinkRx copay offer letting eligible commercially insured patients pay as little as $0.
CEO Steve Basta said the company continues to grow prescribing depth among gastroenterologists.
An exclusivity fight and a trial readout
A federal court in Washington, D.C., on October 26 granted Phathom's motion to intervene in BDR Pharmaceuticals' suit against the FDA over Voquezna's regulatory exclusivity. The FDA opened a public comment docket on October 23, with comments due November 23.
Phathom says the FDA correctly recognized 10 years of exclusivity for the tablets through May 3, 2032, and intends to defend it "vigorously." A loss could let generic applications be approved earlier than expected, the company warned.
Topline results from its Phase 2 eosinophilic esophagitis trial are expected in the fourth quarter of 2026.
Comments on Voquezna's exclusivity are due to the FDA on November 23.
Sources
- 8-K Filing — Phathom Pharmaceuticals, Inc. (PHAT) — SEC EDGAR
- Exhibit d180192dex991.htm — Phathom Pharmaceuticals, Inc. 8-K exhibit — SEC EDGAR
- Phathom Pharmaceuticals Reports Third Quarter 2026 — globenewswire.com